Published in Clin Neuropsychol on December 12, 2011
Instrumental activities of daily living performance among people with Parkinson's disease without dementia. Am J Occup Ther (2014) 0.85
Cognition in movement disorders: where can we hope to be in ten years? Mov Disord (2014) 0.81
Neuropsychological profiles of an elderly cohort undergoing elective surgery and the relationship between cognitive performance and delirium. J Am Geriatr Soc (2015) 0.78
Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 0.75
Cognition in Adults and Older Adults With Type 1 Diabetes: Chicken or Egg? Diabetes Spectr (2016) 0.75
Multicomponent analysis of a digital Trail Making Test. Clin Neuropsychol (2016) 0.75
Neuropsychological functioning, age, and medication adherence in bipolar disorder. PLoS One (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Adherence to medication. N Engl J Med (2005) 39.77
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology (2009) 3.65
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol (2010) 2.69
Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA (2010) 2.14
Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry (2010) 1.96
Everyday cognition: age and intellectual ability correlates. Psychol Aging (1999) 1.80
Drug adherence in Parkinson's disease. Mov Disord (2004) 1.59
Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord (2010) 1.37
Suboptimal medication adherence in Parkinson's disease. Mov Disord (2005) 1.37
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care (2008) 1.33
Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health (2009) 1.26
Validation of the Hopkins Medication Schedule to identify difficulties in taking medications. J Gerontol A Biol Sci Med Sci (2005) 1.03
Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. Parkinsonism Relat Disord (2009) 0.99
Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging (2010) 0.97
Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord (2010) 0.95
Challenges of treatment adherence in older patients with Parkinson's disease. Drugs Aging (2009) 0.92
Everyday reasoning abilities in persons with Parkinson's disease. Mov Disord (2010) 0.83
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
Cognitive impairment and PD patients' capacity to consent to research. Neurology (2013) 3.22
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull (2009) 2.98
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
An odor-specific threshold deficit implicates abnormal intracellular cyclic AMP signaling in schizophrenia. Am J Psychiatry (2008) 2.53
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement (2012) 2.13
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc (2004) 2.00
Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. J Am Geriatr Soc (2008) 1.92
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord (2009) 1.89
Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81
An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry (2011) 1.80
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol (2003) 1.71
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Increase in breast cancer incidence in middle-aged women during the 1990s. Ann Epidemiol (2002) 1.64
Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry (2010) 1.60
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. Mov Disord (2011) 1.57
The Penn Conditional Exclusion Test: a new measure of executive-function with alternate forms of repeat administration. Arch Clin Neuropsychol (2004) 1.57
Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord (2008) 1.49
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry (2003) 1.45
Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. Mov Disord (2015) 1.45
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord (2009) 1.38
Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord (2010) 1.37
Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol (2004) 1.34
Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord (2005) 1.32
Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement (2012) 1.31
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Facial emotion perception in depression and bipolar disorder: a quantitative review. Psychiatry Res (2011) 1.27
Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord (2008) 1.27
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 1.24
Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord (2010) 1.22
Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain (2011) 1.22
Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry (2013) 1.20
Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol (2010) 1.20
Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res (2003) 1.19
Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol (2008) 1.18
Suicidal and death ideation in Parkinson's disease. Mov Disord (2008) 1.17
Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med (2005) 1.15
Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. Parkinsonism Relat Disord (2010) 1.14
Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull (2005) 1.13
Defining and diagnosing involuntary emotional expression disorder. CNS Spectr (2006) 1.12
Genetic influences on cognitive decline in Parkinson's disease. Mov Disord (2012) 1.10
Decrements in volume of anterior ventromedial temporal lobe and olfactory dysfunction in schizophrenia. Arch Gen Psychiatry (2003) 1.09
Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophr Bull (2009) 1.08
Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease. Am J Geriatr Psychiatry (2009) 1.07
Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord (2013) 1.05
Memory-delineated subtypes of schizophrenia: relationship to clinical, neuroanatomical, and neurophysiological measures. Neuropsychology (2002) 1.04
Olfactory dysfunction in Parkinson's disease. Neurosignals (2007) 1.04
Low olfactory bulb volume in first-degree relatives of patients with schizophrenia. Am J Psychiatry (2003) 1.03
Physiologic impairment of olfactory stimulus processing in schizophrenia. Biol Psychiatry (2003) 1.03
Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord (2010) 1.03
Cognitive impairment in nondemented Parkinson's disease. Mov Disord (2011) 1.01
Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol (2007) 0.99
Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol (2007) 0.98
Lewy body dementia: the caregiver experience of clinical care. Parkinsonism Relat Disord (2010) 0.98
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Dimensions of executive function in Parkinson's disease. Dement Geriatr Cogn Disord (2005) 0.97
Olfactory processing in schizophrenia, non-ill first-degree family members, and young people at-risk for psychosis. World J Biol Psychiatry (2011) 0.96
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96